What is Vicebio?
Vicebio is at the forefront of biotechnology, focusing on redefining respiratory disease prevention through innovative vaccine solutions. The company leverages its proprietary Molecular Clamp technology to develop next-generation vaccines offering broad protection and ease of manufacturing. Vicebio's commitment lies in addressing significant global health challenges with a robust pipeline of multipathogen respiratory vaccines, targeting healthcare providers and organizations seeking advanced disease management solutions.
How much funding has Vicebio raised?
Vicebio has raised a total of $100M across 1 funding round:
Series B
$100M
Series B (2024): $100M with participation from TCG Crossover, UniQuest, Goldman Sachs, and venBio Partners
Key Investors in Vicebio
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and breakthrough therapies that have the potential to transform healthcare. They aim to invest in innovators within the pharmaceutical and biotechnology sectors.
Goldman Sachs
Goldman Sachs is a leading global investment banking firm providing a wide range of financial services, including mergers and acquisitions advisory, underwriting, and strategic advisory services worldwide. They are known for their influential role in global capital markets.
venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs. They aim to position their portfolio companies for success by addressing key aspects such as intellectual property and clinical trial design.
What's next for Vicebio?
With this substantial enterprise-level funding and a recent strategic investment, Vicebio is poised for significant expansion. The Series B financing indicates a transition from development to scaling operations, likely focusing on advancing its pipeline through clinical trials, expanding manufacturing capabilities, and broadening market reach. The company's strategic focus on multipathogen respiratory vaccines positions it to address critical unmet needs in global health, with future growth expected to be driven by strategic partnerships and market penetration.
See full Vicebio company page
